Drugs & Aging

, Volume 29, Issue 7, pp 523–531 | Cite as

Evolution of Topical NSAIDs in the Guidelines for Treatment of Osteoarthritis in Elderly Patients

Current Opinion

Abstract

Increasing age is the primary predictor of osteoarthritis, the most prevalent painful condition in the US. Because there are no disease-modifying therapies for osteoarthritis, relief of symptoms and maintenance of quality of life through improving joint function become the focus of management. Although highly effective for pain relief, oral nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with systemic adverse reactions that are sometimes treatment limiting, especially for older patients. Thus, osteoarthritis management in elderly populations is shifting away from traditional NSAIDs to therapies that provide comparable pain relief with improved safety. Since the approval by the US Food and Drug Administration of the use of topical NSAIDs to manage osteoarthritis pain, current treatment guidelines put forth by several professional societies have begun to recommend topical NSAIDs as an alternative therapy and, most recently, as first-line therapy for osteoarthritis management in the elderly. This review provides an overview of the various treatment guidelines that are available to assist prescribers in making safe and effective decisions in the treatment of osteoarthritis in this high-risk patient population.

References

  1. 1.
    Lawrence RC, Felson DT, Helmick CG, et al., on behalf of the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum 2008 Jan; 58 (1): 26–35.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Sadosky AB, Bushmakin AG, Cappelleri JC, et al. Relationship between patient-reported disease severity in osteoarthritis and self-reported pain, function and work productivity. Arthritis Res Ther 2010; 12 (4): R162. doi: 10.1186/ar3121.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Altman RD, Barthel HR. Topical therapies for osteoarthritis. Drugs 2011; 71 (10): 1259–79.PubMedCrossRefGoogle Scholar
  4. 4.
    Centers for Disease Control and Prevention. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation — United States, 2007–2009. MMWR Morb Mortal Wkly Rep 2010 Oct 8; 59 (39): 1261–5.Google Scholar
  5. 5.
    Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998 Aug; 41 (8): 1343–55.PubMedCrossRefGoogle Scholar
  6. 6.
    Rossignol M, Leclerc A, Allaert FA, et al. Primary osteoarthritis of hip, knee, and hand in relation to occupational exposure. Occup Environ Med 2005 Nov; 62 (11): 772–7.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Grotle M, Hagen KB, Natvig B, et al. Prevalence and burden of osteoarthritis: results from a population survey in Norway. J Rheumatol 2008 Apr; 35 (4): 677–84.PubMedGoogle Scholar
  8. 8.
    Salaffi F, Carotti M, Stancati A, et al. Health-related quality of life in older adults with symptomatic hip and knee osteoarthritis: a comparison with matched healthy controls. Aging Clin Exp Res 2005 Aug; 17 (4): 255–63.PubMedCrossRefGoogle Scholar
  9. 9.
    Centers for Disease Control and Prevention (CDC). Osteoarthritis. Atlanta (GA): CDC, 2010 [online]. Available from URL: http://www.cdc.gov/arthritis/basics/osteoarthritis.htm [Accessed 2011 Aug 8].
  10. 10.
    Hochberg MC, Altman RD, Toupin April K, et al. American College of Rheumatology 2012 recommendations for the use of non-pharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012 Apr; 64 (4): 465–74.CrossRefGoogle Scholar
  11. 11.
    Jordan KM, Arden NK, Doherty M, et al., on behalf of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003 Dec; 62 (12): 1145–55.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    National Institute for Health and Clinical Excellence. Osteoarthritis: the care and management of osteoarthritis in adults. London: National Institute for Health and Clinical Excellence, 2008 Feb. NICE clinical guideline 59.Google Scholar
  13. 13.
    Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008 Feb; 16 (2): 137–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy: recognition and response. Arch Intern Med 1987 Dec; 147 (12): 2093–100.PubMedCrossRefGoogle Scholar
  15. 15.
    Roth SH. Nonsteroidal antiinflammatory drug gastropathy: we started it, why don’t we stop it? J Rheumatol 2005 Jul; 32(7): 1189–91.PubMedGoogle Scholar
  16. 16.
    Bombardier C, Laine L, Reicin A, et al., on behalf of the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New Engl J Med 2000 Nov 23; 343 (21): 1520–8.CrossRefGoogle Scholar
  17. 17.
    Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl J Med 2005 Mar 17; 352 (11): 1092–102.PubMedCrossRefGoogle Scholar
  18. 18.
    Lévesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005 Apr 5; 142 (7): 481–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Solomon SD, McMurray JJ, Pfeffer MA, et al., on behalf of the Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med 2005 Mar 17; 352 (11): 1071–80.PubMedCrossRefGoogle Scholar
  20. 20.
    Becker MC, Wang TH, Wisniewski L, et al., on behalf of the PRECISION Investigators. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J 2009 Apr; 157 (4): 606–12.PubMedCrossRefGoogle Scholar
  21. 21.
    Turajane T, Wongbunnak R, Patcharatrakul T, et al. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. J Med Assoc Thai 2009 Dec; 92 Suppl. 6: S19–26.PubMedGoogle Scholar
  22. 22.
    Hinz B, Dormann H, Brune K. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 2006 Jan; 54 (1): 282–91.PubMedCrossRefGoogle Scholar
  23. 23.
    Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioidinduced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007 Jul; 61 (7): 1181–7.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 2010 Jan; 112 (1): 226–38.PubMedCrossRefGoogle Scholar
  25. 25.
    Tey HL, Yosipovitch G. Targeted treatment of pruritus: a look into the future. Br J Dermatol 2011 Jul; 165 (1): 5–17.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Roy S, Wang J, Kelschenbach J, et al. Modulation of immune function by morphine: implications for susceptibility to infection. J Neuroimmune Pharmacol 2006 Mar; 1 (1): 77–89.PubMedCrossRefGoogle Scholar
  27. 27.
    Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The DAWN report: emergency department visits involving adverse reactions to medications among older adults. Rockville (MD): US Department of Health and Human Services, 2011 Feb 24. SAMHSA Publication no. DAWN 013.Google Scholar
  28. 28.
    Walker PC, Alrawi A, Mitchell JF, et al. Medication use as a risk factor for falls among hospitalized elderly patients. Am J Health Syst Pharm 2005 Dec 1; 62 (23): 2495–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Hausdorff JM, Rios DA, Edelberg HK. Gait variability and fall risk in community-living older adults: a 1-year prospective study. Arch of Phys Med Rehabil 2001 Aug; 82 (8): 1050–6.CrossRefGoogle Scholar
  30. 30.
    Alexander BH, Rivara FP, Wolf ME. The cost and frequency of hospitalization for fall-related injuries in older adults. Am J Public Health 1992 Jul; 82 (7): 1020–3.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med 2010 Dec 13; 170 (22): 1979–86.PubMedCrossRefGoogle Scholar
  32. 32.
    Guo Z, Wills P, Viitanen M, et al. Cognitive impairment, drug use, and the risk of hip fracture in persons over 75 years old: a community-based prospective study. Am J Epidemiol 1998 Nov 1; 148 (9): 887–92.PubMedCrossRefGoogle Scholar
  33. 33.
    Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 1999 Jan; 47 (1): 40–50.PubMedGoogle Scholar
  34. 34.
    Miller M, Stürmer T, Azrael D, et al. Opioid analgesics and the risk of fractures in older adults with arthritis. J Am Geriatr Soc 2011 Mar; 59 (3): 430–8.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Von Korff M, Merrill JO, Rutter CM, et al. Time-scheduled vs. pain-contingent opioid dosing in chronic opioid therapy. Pain 2011 Jun; 152 (6): 1256–62.CrossRefGoogle Scholar
  36. 36.
    American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009 Aug; 57 (8): 1331–46.CrossRefGoogle Scholar
  37. 37.
    Perucca E. Age-related changes in pharmacokinetics: predictability and assessment methods. Int Rev Neurobiol 2007; 81: 183–99.PubMedCrossRefGoogle Scholar
  38. 38.
    Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging 2001; 18 (11): 837–51.PubMedCrossRefGoogle Scholar
  39. 39.
    Wynne H. Drug metabolism and ageing. J Br Menopause Soc 2005 Jun; 11 (2): 51–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Arnstein P. Balancing analgesic efficacy with safety concerns in the older patient. Pain Manag Nurs 2010 Jun; 11 (2 Suppl.): S11–22.PubMedCrossRefGoogle Scholar
  41. 41.
    Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs 2000 Sep; 60 (3): 555–74.PubMedCrossRefGoogle Scholar
  42. 42.
    Jorge LL, Feres CC, Teles VE. Topical preparations for pain relief: efficacy and patient adherence. J Pain Res 2010 Dec 20; 4: 11–24.CrossRefGoogle Scholar
  43. 43.
    Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009 Jun; 143 (3): 238–45.PubMedCrossRefGoogle Scholar
  44. 44.
    Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004 Oct; 31 (10): 2002–12.PubMedGoogle Scholar
  45. 45.
    Makris UE, Kohler MJ, Fraenkel L. Adverse effects of topical nonsteroidal antiinflammatory drugs in older adults with osteoarthritis: a systematic literature review. J Rheumatol 2010 Jun; 37 (6): 1236–43.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Roth SH, Fuller P. Diclofenac topical solution compared with oral diclofenac: a pooled safety analysis. J Pain Res 2011; 4: 159–67.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Lin J, Zhang W, Jones A, et al. Efficacy of topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ 2004 Aug; 329 (7461): 324. doi: 10.1136/bmj.38159. 639028.7C.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206–52.PubMedCrossRefGoogle Scholar
  49. 49.
    Jakobsson U, Hallberg IR. Quality of life among older adults with osteoarthritis: an explorative study. J Gerontol Nurs 2006 Aug; 32 (8): 51–60.PubMedGoogle Scholar
  50. 50.
    Carr DB. When bad evidence happens to good treatments. Reg Anesth Pain Med 2008 May–Jun; 33 (3): 229–40.PubMedCrossRefGoogle Scholar
  51. 51.
    American Academy of Orthopaedic Surgeons (AAOS). Treatment of osteoarthritis of the knee (non-arthroplasty). Rosemont (IL): AAOS, 2008 [online]. Available from URL: http://www.aaos.org/research/guidelines/OAKguideline.pdf [Accessed 2011 Aug 1].
  52. 52.
    Lim AY, Doherty M. What of guidelines for osteoarthritis? Int J Rheum Dis 2011 May; 14 (2): 136–44.PubMedCrossRefGoogle Scholar
  53. 53.
    Simon LS, Lipman AG, Jacox AK, et al. Guideline for the management of pain in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis. 2nd ed. Glenview (IL): American Pain Society, 2002. Clinical practice guidelines no. 2.Google Scholar
  54. 54.
    Towheed TE, Maxwell L, Judd MG, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006 Jan 25; (1): CD004257.Google Scholar
  55. 55.
    Trnavský K, Fischer M, Vögtle-Junkert U, et al. Efficacy and safety of 5% ibuprofen cream treatment in knee osteoarthritis: results of a randomized, double-blind, placebo-controlled study. J Rheumatol 2004 Mar; 31 (3): 565–72.PubMedGoogle Scholar
  56. 56.
    Niethard FU, Gold MS, Solomon GS, et al. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol 2005 Dec; 32 (12): 2384–92.PubMedGoogle Scholar
  57. 57.
    Mason L, Moore RA, Edwards JE, et al. Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ 2004 Apr 24; 328 (7446): 995. doi: 10.1136/bmj.38040.607141.EE.PubMedCentralPubMedCrossRefGoogle Scholar
  58. 58.
    Voltaren® Gel (diclofenac sodium topical gel) 1% [US prescribing information]. Chadds Ford (PA): Endo Pharmaceuticals Inc., 2009.Google Scholar
  59. 59.
    PENNSAID® (diclofenac sodium topical solution) 1.5% w/w [US prescribing information]. Hazelwood (MO): Mallinckrodt Brand Pharmaceuticals, Inc., 2010.Google Scholar
  60. 60.
    US Food and Drug Administration. FDA drug safety communication: Voltaren Gel (diclofenac sodium topical gel) 1%: hepatic effects labeling changes. 2009 Dec 4 [online]. Available from URL: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm193047.htm [Accessed 2011 Aug 9].
  61. 61.
    Matthews P, Derry S, Moore RA, et al. Topical rubefacients for acute and chronic pain in adults. Cochrane Database Syst Rev 2009 Jul 8; (3): CD007403.Google Scholar
  62. 62.
    O’Malley P. Sports cream and arthritic rubs: the hidden dangers of unrecognized salicylate toxicity. Clin Nurse Spec 2008 Jan–Feb; 22 (1): 6–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Chyka PA, Erdman AR, Christianson G, et al. Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2007; 45 (2): 95–131.CrossRefGoogle Scholar
  64. 64.
    Tiso RL, Tong-Ngork S, Fredlund KL. Oral versus topical ibuprofen for chronic knee pain: a prospective randomized pilot study. Pain Physician 2010 Sep–Oct; 13 (5): 457–67.PubMedGoogle Scholar
  65. 65.
    Chan FK. Primer: managing NSAID-induced ulcer complications: balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol 2006 Oct; 3 (10): 563–73.PubMedCrossRefGoogle Scholar
  66. 66.
    Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009 May; 103 (9): 1227–37.PubMedCrossRefGoogle Scholar
  67. 67.
    Lazzaroni M, Porro GB. Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors. Drugs 2009; 69 (1): 51–69.PubMedCrossRefGoogle Scholar
  68. 68.
    McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006 Oct 4; 296 (13): 1633–44.PubMedCrossRefGoogle Scholar
  69. 69.
    Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007 Aug 3; 8: 73. doi: 10.1186/1471-2474-8–73.Google Scholar
  70. 70.
    Ofman JJ, MacLean CH, Straus WL, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002 Apr; 29 (4): 804–12.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.Clinical Nurse Specialist for Pain ReliefMassachusetts General HospitalBostonUSA

Personalised recommendations